Analyst Price Targets — AGEN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 29, 2024 11:34 am | Emily Bodnar | H.C. Wainwright | $7.00 | $3.57 | StreetInsider | H.C. Wainwright Reiterates Neutral Rating on Agenus Inc. (AGEN) |
| July 19, 2024 8:55 am | Biren Amin | Jefferies | $7.00 | $5.99 | StreetInsider | Jefferies Downgrades Agenus Inc. (AGEN) to Hold |
| July 19, 2024 4:59 am | Colleen Kusy | Robert W. Baird | $8.00 | $7.30 | TheFly | Agenus downgraded to Neutral from Outperform at Baird |
| July 18, 2024 12:33 pm | Emily Bodnar | H.C. Wainwright | $9.00 | $7.98 | TheFly | Agenus downgraded to Neutral from Buy at H.C. Wainwright |
| July 1, 2024 6:42 am | Emily Bodnar | H.C. Wainwright | $20.00 | $8.38 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Agenus Inc. (AGEN) |
Latest News for AGEN
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The payment was triggered by contracted work orders for critical chemistry, manufacturing and controls (CMC) and production activities…
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Agenus--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-end 2025 financial results before the market opens on Monday, March 16, 2026. Agenus will host a stakeholder briefing webcast in late March to spotlight key strategic plans, data milestones and provide an update on the…
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACRIO26--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced new translational and clinical biomarker data from its Phase 1b C-800-01 trial (NCT03860272) evaluating botensilimab (BOT), an Fc-enhanced anti–CTLA-4 antibody, in combination with balstilimab (BAL), an anti–PD-1 antibody. The data were presented today at the American Association for Cancer…
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACRIO--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program have been accepted for poster presentation at the American Association for Cancer Research- Immuno-Oncology (AACR-IO) Conference, taking place in Los Angeles, CA on February 18–21, 2026.…
Agenus Inc. (AGEN) Discusses Zydus Collaboration, Global Manufacturing Expansion, and Patient Access Initiatives Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AGEN.
U.S. House Trading
No House trades found for AGEN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.